top of page

Secondary cytoreduction followed by chemotherapy vs chemotherapy alone

Writer's picture: Women's Cancer Research FoundationWomen's Cancer Research Foundation

Secondary cytoreduction followed by chemotherapy vs chemotherapy alone in platinum-sensitive relapsed ovarian cancer.

In a recent Lancet Oncology study, Shi et al. (2021) reported on their results comprising patients with platinum-sensitive relapsed ovarian cancer (an ovarian cancer patient demonstrating a favorable clinical response to platinum chemotherapy following the end of first-line platinum-based chemotherapy) with potentially resectable disease (the disease could be further reduced with a secondary surgery). The study patients were randomly assigned 1:1 to undergo secondary surgery followed by chemotherapy (paclitaxel or docetaxel with carboplatin) or chemotherapy alone (no surgery). A total of 357 patients were enrolled in the study, 182 assigned to the surgery and chemotherapy group and 175 assigned to the chemotherapy alone group. Outcomes revealed significantly longer progression-free survival (the length of time during and after the treatment of a disease wherein a patient lives with the disease but the condition does not deteriorate) for the platinum-sensitive relapsed ovarian cancer patients who were treated with secondary surgery followed by chemotherapy vs the patients who were treated with chemotherapy alone. In the surgery and chemotherapy group, median progression-free survival was 17.4 months, while the median progression-free survival was 11.9 months in the chemotherapy alone group. The implications from this study suggest that patients with platinum-sensitive ovarian cancer should discuss the potential of secondary cytoreductive surgery with their treating physician.


About Women’s Cancer Research Foundation The Women’s Cancer Research Foundation (WCRF) is one of Southern California’s and the nation’s most active research organizations for female cancers. We are dedicated to serving the interests of patients, families, and friends affected by women’s cancers. WCRF partners with physician-scientists nationally to make differences in women’s lives by offering hope, strength, and progress.


361 Hospital Road, Suite 422

Newport Beach, CA 92663

PH: (949) 642-5165

29 views0 comments

コメント


FORMERLY KNOWN AS THE NANCY YEARY WOMEN'S CANCER RESEARCH FOUNDATION
IN MEMORY OF NANCY AND BOB YEARY

ABOUT US 

Since 1985, the physicians and researchers at the WCRF have been at the forefront of pioneering clinical research, aimed at enhancing cure rates among women diagnosed with breast, ovarian, uterine, and cervical cancers. WCRF actively engages in designing, conducting, and disseminating groundbreaking research focused on cutting-edge medical treatments.


Furthermore, WCRF serves as a vital hub for both foundational and applied research, as well as education, pertaining to the latest advancements in the treatment of breast and gynecologic cancers. In addition to conducting and publishing original research, the WCRF, provides valuable clinical information to physicians and patients alike.
 

 

Subscribe to Our Newsletter

Thanks for submitting!

CONTACT 

T: 949-642-5165

F: 949-646-7157

699 Diamond Street
Laguna Beach, CA 92651

  • Womens Cancer Research Foundation on X
  • LinkedIn
  • Facebook
  • YouTube
  • Instagram
Wpmen's Cancer Research Foundation

© 2025 Women's Cancer Research Foundation All rights reserved.

Website design by Tribe of Digital Natives

bottom of page